Carl E Frasch

Summary

Country: USA

Publications

  1. doi request reprint Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
    Carl E Frasch
    Frasch Biologics Consulting, PO Box 986, Martinsburg, WV, USA 25402
    Vaccine 27:B112-6. 2009
  2. doi request reprint Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges
    Carl E Frasch
    Frasch Biologics Consulting, PO Box 986, Martinsburg, WV 25402, USA
    Vaccine 27:6468-70. 2009
  3. doi request reprint Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM)
    Carl E Frasch
    Frasch Biologics Consulting, Martinsburg, West Virginia, USA
    Hum Vaccin Immunother 8:715-24. 2012

Detail Information

Publications3

  1. doi request reprint Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
    Carl E Frasch
    Frasch Biologics Consulting, PO Box 986, Martinsburg, WV, USA 25402
    Vaccine 27:B112-6. 2009
    ..3) Meningococcal polysaccharide, polysaccharide-protein conjugates, and outer membrane vesicle vaccines all induce SBA shown to be effective in direct proportion to the percent of vaccinees with SBA activity...
  2. doi request reprint Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges
    Carl E Frasch
    Frasch Biologics Consulting, PO Box 986, Martinsburg, WV 25402, USA
    Vaccine 27:6468-70. 2009
    ..Two major measures used to follow vaccine stability are changes in molecular size and percent free (unbound) PS...
  3. doi request reprint Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM)
    Carl E Frasch
    Frasch Biologics Consulting, Martinsburg, West Virginia, USA
    Hum Vaccin Immunother 8:715-24. 2012
    ..We summarize the laboratory and clinical studies leading to prequalification of MenAfriVac(TM). The 2011 epidemic season ended with no reported case of group A meningitis in vaccinated individuals...